Floatz logo

Nextgen-Til

Malignant Solid Tumor

Vall d'Hebron Institute of OncologyCell therapyEarly Phase 1Active
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
81/ 100

Competitive context

44 Active assets in the Malignant Solid Tumor cohort.

Asset / SponsorPhaseRating
Nivolumab
Bristol-Myers Squibb
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Genmab
Phase 2B
Irinotecan
Tianjin Medical University Cancer Institute and Hospital
Phase 2B
IMMUNOGLOBULIN G1, ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYPE VEGFR-2 EXTRACELLULAR DOMAIN) (HUMAN MONOCLONAL IMC-1121B .GAMMA.-CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL IMC-1121B .KAPPA.-CHAIN, DIMER
Eli Lilly and Company
Phase 2B
(+)-VINCRISTINE
Tianjin Medical University Cancer Institute and Hospital
Phase 2B

View all 50 →

Same molecule, other indications

Nextgen-Til is also rated in:

carcinomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →